Skip to content

Medicare to Cover Crosslinking from May 1, 2018

Press release from the Royal Australian and New Zealand College of Ophthalmologists Keratoconus treatment Corneal Collagen Cross Linking to be supported by Medicare In a much awaited development, Corneal Collagen Cross Linking (CCXL) for keratoconus will be added to the Medicare Benefits Scheme from 1 May 2018. This exciting news is welcomed by the Royal Australian

Read More

Your Top 12 Crosslinking Questions—Answered!

New to corneal collagen crosslinking? This Q&A guide from Wills Eye Hospital will help prepare you to manage keratoconus patients in the new era. This guide to crosslinking for ophthalmologists may be of interest to you too.

First results from Australian Crosslinking Registry

The head of the Australian Crosslinking Registry, Professor Stephanie Watson, presented the latest results from the registry on crosslinking at meetings in Melbourne and Sydney. The full video of her presentation can be viewed here Her slideshow presentation (pdf format) can be downloaded below Professor Watson Nov 2017 talk

Cross-linking stabilises keratoconus

Optometry Australia News   Collagen corneal cross-linking appears to stabilise keratoconus in patients who undergo the procedure, according to early results of a world-first keratoconus registry based in Australia. Ophthalmologist Professor Stephanie Watson has completed initial analysis of data from 1,062 keratoconic patients in Australia and New Zealand including adults, teenagers and children who had

Read More

Is Cross-linking at a Crossroads?

FDA-approved corneal collagen cross-linking is barely a year old (in the United States). The Avedro KXL UV system, along with Photrexa and Photrexa Viscous, is approved for patients aged 14 and up with progressive keratoconus or post-surgical ectasia. After years of commercial use abroad, this long-awaited therapeutic option has the potential to halt vision loss

Read More

Recent Innovations in Collagen Corneal Cross-linking; a Mini Review

1. INTRODUCTION Corneal cross-linking (CXL) was introduced in the late 1990s by Seiler et al. [1, 2]. Until that time the conservative therapeutic approach of Keratoconus and other corneal ectatic diseases, involved mostly the fitting of hard contact lenses as an improvement of corrected visual acuity and as a mean to halt the progression through corneal adaptation on

Read More

A closer look at riboflavin application for corneal collagen crosslinking

Take-home message: Corneal collagen crosslinking with riboflavin works well but requires further exploration to identify the best approach for various types of patients. By Vanessa Caceres New riboflavin formulations for corneal collagen crosslinking (CXL) could make the procedure more effective for keratoconus and ectasia, said George O. Waring IV, MD, FACS, director of refractive surgery,

Read More

Standardized definitions, endpoints should drive cross-linking trials

Inclusion criteria, definitions of progression and endpoints vary, resulting in a lack of standardized data. Ocular Surgery News U.S. Edition, August 10, 2015 As clinical trials for corneal collagen cross-linking proceed, clinicians should use standardized definitions and metrics to evaluate the effectiveness of treatment, according to a speaker at the World Cornea Congress in San

Read More